Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Hims & Hers announced that they will offer a low stock price of the composite version Wegovy to specific professional groups in the USA.
Gelonghui September 19th | American remote medical services company Hims & Hers Health announced on Wednesday the launch of a new plan, offering a compounded version of Novo Nordisk's weight loss drug Wegovy at a discounted price of $99 per month to certain occupational patients. This pricing will be applicable to eligible US military personnel, teachers, nurses, police officers, firefighters, and veterans. According to its website, for patients participating in a 12-month treatment plan, the price of Semaglutide injectable solution is $199 per month. The company stated that the compounded GLP-1 injectable solution is developed by Hims &
US stocks closed | After the interest rate cut, US stocks rose and then fell back, with the three major indices closing slightly lower. Apple bucked the trend and rose nearly 2%.
After the Federal Reserve cut interest rates, US stock index hit a new daily high. However, it turned downwards after Powell's press conference. The S&P 500 ended its seven-day winning streak, while the Dow Jones Industrial Average fell for the second consecutive day. Nvidia failed to rebound and closed down nearly 2%, while Apple rose against the trend, gaining nearly 2%.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
Express News | The CEO of Novartis said that Novartis will not join the weight loss drug craze.
NanoVation Therapeutics Announces Multi-Year Partnership With Novo Nordisk To Develop Genetic Medicines Targeting Cardiometabolic And Rare Diseases, With Potential Payments Up To $600M And Tiered Royalties
Bullish on US stocks | More policy support! Li Auto Inc. jumped over 12% overnight; Rate cut expectations boost credit card companies to hit new historical highs.
Heavy investment! Blackrock joined hands with Microsoft to bet on the AI track, reaching the $900 mark overnight and hitting a new historical high, with a 1.04% increase; target price was raised by major bank analysts! Applovin, a mobile advertising technology company, soared more than 6% overnight, surging more than 40% in the past 5 trading days, and has risen more than 200% so far this year, creating a new historical high again.
Unhappy with the high stock price of weight-loss drugs, US senators are pressuring Novo-Nordisk: generic drug prices can be lower than $100/month.
Generic drug companies can sell generic versions of novo-nordisk a/s (NVO.US) diabetes drug Ozempic for less than $100 per month.
Novo Nordisk: Diabetes drug Ozempic may become a new target for price negotiations in the USA.
On September 18th, Ulrich Otte, Senior Vice President of Finance and Operations at Novo Nordisk, said that the popular diabetes drug Ozempic is likely to become one of the next targets for drug price negotiations by the US government, and the company is prepared for this. Ozempic is priced at about $968 per month in the United States, and most Medicare plans for type 2 diabetes patients cover Ozempic to control their blood sugar levels. The Centers for Medicare & Medicaid Services will announce the next batch of 15 retail prescription drugs for price reductions under the "Reducing Inflation Act" by February 1st of next year."
Weight-loss Drug Competition Heats up With Growing Pill Market
Benzinga Market Summary: Bitcoin Rises, Oil Gains On Supply Impacts, Novo Nordisk Falls Amid Pricing Comments From Exec And Criticism From Sen. Sanders
Sector Update: Health Care Stocks Retreat Late Afternoon
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations, Bloomberg Reports
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Express News | Novo Nordisk executive Otte: The company is prepared to participate in the next round of drug price negotiations with the US government, and the weight-loss drug Ozempic is "very likely" to be one of the subjects of the negotiations.
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target